Abstract 2979
Background
Despite advances in early detection, diagnosis, and treatment of oral squamous cell carcinoma (OSCC), the survival for patients with early stage remains at approximately 80% for the past 30 years. Regional lymph node metastasis is an important prognostic factor. Therefore, early detection of the cervical lymph nodes metastasis is expected to further improve survival. Sentinel lymph node biopsy (SLNB) is a widely accepted procedure in various human malignancies. In clinically N0 (cN0) early OSCC cases, SLNB has received considerable attention for its role in deciding whether to perform neck dissection. The objective in this study is to investigate the topographical distribution of sentinel lymph nodes (SLNs) and occult metastatic lymph nodes in early tongue squamous cell carcinoma (TSCC).
Methods
A total of 64 patients with T1/2N0 TSCC underwent SLNB between 2001 and 2016. The location of SLNs was determined by radioisotope (RI) method with preoperative lymphoscintigraphy and intraoperative use of a handheld gamma probe, and evaluated by histopathological and genetic examinations. Patients with metastatic lymph nodes were treated with completion neck dissection. Excised lymph nodes were grouped into the neck level according to the international guidelines.
Results
SLNs were successfully identified with RI method (100%). The rate of SLN identified side was 84.5% in ipsilateral, 12.1% in bilateral, and 3.4% in contralateral. Nine of 64 patients (14.1%) had metastasis-positive SLN. Six patients with negative SLN developed the latent neck lymph node metastasis. There was no patients with metastatic involvement of neck level IV and V. The sensitivity, specificity, and accuracy was 60% (9/15), 100% (49/49), and 90.6% (58/64), respectively.
Conclusions
SLNB is a minimally invasive and highly reliable method staging the cN0 for patients with early OSCC. Completion neck dissection of level I-III in SLNB-positive patients might be sufficient in patients with early TSCC. Our study showed that SLNB was helpful in clarifying unexpected bilateral or contralateral metastatic drainage patterns. SLNB provides more accurate staging than elective neck dissection or wait and see policy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4634 - Comparative molecular analyses between microsatellite stable BRAFV600E mutant colorectal cancers and BRAFV600E mutant melanomas.
Presenter: Mohamed Salem
Session: Poster Display session 3
Resources:
Abstract
3264 - A novel preclinical model of RAF-independent MEK1 mutant tumors and its treatment with novel ATP competitive MEK inhibitor
Presenter: Luca Hegedus
Session: Poster Display session 3
Resources:
Abstract
4918 - HER2 inhibition in Aggressive Squamous Cell Carcinomas driven by a common MET Sema Domain Polymorphism
Presenter: Nur Afiqah Mohamed Salleh
Session: Poster Display session 3
Resources:
Abstract
2426 - ADAM9 as a target for lung cancer treatment
Presenter: Yuh-pyng Sher
Session: Poster Display session 3
Resources:
Abstract
5537 - Novel polyurea/polyurethane nanocapsules loaded with a tambjamine analog to improve cancer chemotherapy delivery and safety in lung cancer
Presenter: Marta Perez Hernandez
Session: Poster Display session 3
Resources:
Abstract
1597 - Discovery of Clinical Candidate DBPR112, a Furanopyrimidine-based Epidermal Growth Factor Receptor Inhibitor for the Treatment of Non-Small Cell Lung Cancer
Presenter: Hsing-pang Hsieh
Session: Poster Display session 3
Resources:
Abstract
3543 - Molecular characteristics in lung squamous cell carcinomas dependent on TP53 status – putative targets
Presenter: Vilde Haakensen
Session: Poster Display session 3
Resources:
Abstract
4111 - Comparison of molecular profiles between primary tumour and matched metastasis in non-small cell lung cancer
Presenter: Asuka Kawachi
Session: Poster Display session 3
Resources:
Abstract
4559 - Treatment with BLU-667, a potent and selective RET inhibitor, provides rapid clearance of ctDNA in Patients with RET-altered Non-Small Cell Lung Cancer (NSCLC) and Thyroid Cancer
Presenter: Giuseppe Curigliano
Session: Poster Display session 3
Resources:
Abstract
2501 - Triple MET/SRC/PIM inhibition in MET addicted tumors
Presenter: Ilaria Attili
Session: Poster Display session 3
Resources:
Abstract